ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Gujarat Themis Biosyn Earnings Call: Key Takeaways

Gujarat Themis Biosyn Limited reports Q4 FY26 revenue of ₹44.23 cr (+17.2% YoY) and PAT of ₹10.89 cr. Management announced two major inorganic acquisitions to pivot towards a CDMO model.

Why this was an Alfa AlertNot a filter event. Results are strong but do not represent a 10% beat over management-stated prior guidance.
Highlights
Revenue growth17.2% YoY in Q4; 10% for FY26.
MarginsEBITDA margins expanded due to operational efficiencies.
Demand visibilitySteady and resilient market demand mentioned.
Management confidenceHigh, citing 'strong note' conclusion to fiscal year.

Growth

FY26 Revenue grew 10% to ₹165.82 cr; EBITDA grew 9.7% to ₹75.53 cr. Q4 EBITDA margins expanded to 43.77%.

Outlook

Acquiring 13 Sanofi brands (~EUR 62 Mn revenue) and 100% of MicroBiopharm Japan (~INR 575 Cr revenue). New R&D/API units operational.

Risks

Rising manpower costs and other operating expenses. Integration risks associated with major overseas acquisitions.

Source

Earnings Call filed with BSE, NSE: GUJTHEM. Summary written with AI assistance from the document.

Read the document ↗

Gujarat Themis Biosyn Ltd: key numbers

Share price
₹389.15
Market cap
₹5,065 Cr
Revenue (annual)
₹165.8 Cr
Net profit (annual)
₹46.68 Cr
P/E (TTM)
104.0×Sector 43.8×
Promoter holding
59.33%-11.53% QoQ
FII holding
3.80%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Gujarat Themis Biosyn Ltd

All →